China SXT Pharmaceuticals (SXTC) Intangibles (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Intangibles of $6328.0 for Q1 2026, down 46.41% year-on-year from $11808.0 in Q1 2025, and down 25.83% on a QoQ basis from $8532.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Intangibles (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals (SXTC) has reported Intangibles for 9 consecutive years, with $6328.0 the latest figure, recorded in Q1 2026.
- Quarterly Intangibles fell 46.41% year-over-year to $6328.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6328.0 (down 46.41% YoY) and the FY2026 annual result came in at $6328.0, down 46.41% from the prior year.
- Intangibles eased to $6328.0 in Q1 2026 per SXTC's latest filing, from $8532.0 in the prior quarter.
- Over the last five years, Intangibles for SXTC reached as high as $85728.0 in Q1 2022 and fell as low as $6328.0 in Q1 2026.
- A 5-year average of $25389.0 and a median of $19101.0 in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles grew 3.35% — and 2023, when it tumbled 67.49%.
- Year by year, Intangibles stood at $30724.0 in 2022, then slipped by 26.72% to $22514.0 in 2023, then slipped by 29.39% to $15898.0 in 2024, then tumbled by 46.33% to $8532.0 in 2025, then fell by 25.83% to $6328.0 in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $6328.0, $8532.0, and $11808.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 473.93 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.23 Bn |
| 10 | China SXT Pharmaceuticals | 7.11 Mn | -21.06 Mn | - | 6,328.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,328.00 |
| Sep 30, 2025 | 8,532.00 |
| Mar 31, 2025 | 11,808.00 |
| Sep 30, 2024 | 15,898.00 |
| Mar 31, 2024 | 19,101.00 |
| Sep 30, 2023 | 22,514.00 |
| Mar 31, 2023 | 27,868.00 |
| Sep 30, 2022 | 30,724.00 |
| Mar 31, 2022 | 85,728.00 |
| Sep 30, 2021 | 42,353.00 |
| Mar 31, 2021 | 82,948.00 |
| Sep 30, 2020 | 48,198.00 |
| Mar 31, 2020 | 76,750.00 |
| Sep 30, 2019 | 53,386.00 |
| Mar 31, 2019 | 80,979.00 |
| Sep 30, 2018 | 52,077.00 |
| Mar 31, 2018 | 60,673.00 |